FEMY News and Press, Femasys Inc. From 03/24/22

Femasys press release (NASDAQ:FEMY): FY GAAP EPS of -$1.12. Revenue of $1.18M (+13.5% Y/Y). The cash and cash equivalents balance as of December 31, 2021 was $24.78M. For further details see: Femasys GAAP EPS of -$1.12, revenue of $1.18M

-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health -- ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldw...

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...

Gainers: Creative Medical Technology CELZ +99%. 4D pharma LBPS +87%. Femasys FEMY +21%. Revelation Biosciences (REVB) +19%. NeuroSense Therapeutics (NRSN) +7%. Losers: Cue Health (HLTH) -17%. Codex DNA (DNAY) -17%. PetVivo (PETV) -14%. Yumanity The...

Creative Medical Technology (CELZ) +70% announces positive top-line results for StemSpine® Pilot study. 4D pharma LBPS +54% as drug combo meets efficacy goal early in kidney cancer group. Rezolute RZLT +19% with success in mid-stage study for hyperinsulinism ther...

Femasys (NASDAQ:FEMY) has appointed Dov Elefant to Chief Financial Officer (CFO), effective Feb. 28, 2022. Elefant holds 25 years of financial management experience at both public and private biopharmaceutical companies, having served as Vice President and CFO of Cellectar Biosciences most re...

-- Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages -- ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a...

Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...

ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of...

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company i...